Commentary on and Expectation of Tumor Immunotherapy

With the rapid development of tumor immunology, immunotherapy for malignant tumors is becoming a research focus, offering an effective opportunity for the treatment of patients with advanced tumors. Immune checkpoint inhibitors, such as programmed cell death 1 receptor/programmed cell death 1 ligand 1 antibody and CTLA-4 antibody, are an important research hotspot of immunotherapy for advanced cancers. FDA has approved some immune checkpoint antibodies for the treatment of advanced metastatic melanoma, non-small cell lung cancer, renal cell carcinoma, uroepithelium carcinoma, and non-Hodgkin's lymphoma, and the efficacy and safety for above tumors has been confirmed. In addition, chemiric antigen receptor T-cell therapy treatment showed a strong and persistent therapeutic effect for hematologic malignancy, as another successful case of immunotherapy. Cancer vaccine such as Simpuleucel-T was also another milestone in the development of tumor immunotherapy. Currently, immunotherapy for malignant tumors is presenting a promising future.